Do analysts recommend PRPO or BNGO?

Bionano Genomics has a consensus target price of $6.00, indicating a potential upside of 415.02%. Given Bionano Genomics' stronger consensus rating and higher possible upside, analysts clearly believe Bionano Genomics is more favorable than Precipio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precipio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bionano Genomics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PRPO or BNGO more profitable?

Precipio has a net margin of -3.57% compared to Bionano Genomics' net margin of -109.94%. Precipio's return on equity of -6.73% beat Bionano Genomics' return on equity. Company Net Margins Return on Equity Return on Assets Precipio -3.57% -6.73% -4.49% Bionano Genomics -109.94% -71.38% -43.07%

Does the media favor PRPO or BNGO?

In the previous week, Precipio and Precipio both had 5 articles in the media. Precipio's average media sentiment score of 0.52 beat Bionano Genomics' score of 0.46 indicating that Precipio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precipio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bionano Genomics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BNGO or DAIO more profitable?

Data I/O has a net margin of -41.85% compared to Bionano Genomics' net margin of -109.94%. Data I/O's return on equity of -54.33% beat Bionano Genomics' return on equity. Company Net Margins Return on Equity Return on Assets Bionano Genomics -109.94% -71.38% -43.07% Data I/O -41.85% -54.33% -36.75%

Do analysts rate BNGO or AATC?

Bionano Genomics currently has a consensus price target of $6.00, indicating a potential upside of 415.02%. Given Bionano Genomics' stronger consensus rating and higher probable upside, research analysts clearly believe Bionano Genomics is more favorable than Autoscope Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bionano Genomics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Autoscope Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to BNGO or AATC?

In the previous week, Bionano Genomics had 4 more articles in the media than Autoscope Technologies. MarketBeat recorded 5 mentions for Bionano Genomics and 1 mentions for Autoscope Technologies. Bionano Genomics' average media sentiment score of 0.46 beat Autoscope Technologies' score of 0.00 indicating that Bionano Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bionano Genomics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Autoscope Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BNGO or CLIR?

In the previous week, Bionano Genomics had 3 more articles in the media than ClearSign Technologies. MarketBeat recorded 5 mentions for Bionano Genomics and 2 mentions for ClearSign Technologies. ClearSign Technologies' average media sentiment score of 0.93 beat Bionano Genomics' score of 0.46 indicating that ClearSign Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bionano Genomics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ClearSign Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Bionano Genomics (BNGO) Competitors

$1.16 +0.01 (+0.43%)

As of 01:16 PM Eastern

Compare

BNGO vs. PRPO, DAIO, AATC, CLIR, and MSAI

Should you buy Bionano Genomics stock or one of its competitors? MarketBeat compares Bionano Genomics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bionano Genomics include Precipio (PRPO), Data I/O (DAIO), Autoscope Technologies (AATC), ClearSign Technologies (CLIR), and MultiSensor AI (MSAI). These companies are all part of the "measuring and control equipment" industry.

How does Bionano Genomics compare to Precipio?

Precipio (NASDAQ:PRPO) and Bionano Genomics (NASDAQ:BNGO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

Bionano Genomics has a consensus target price of $6.00, indicating a potential upside of 415.02%. Given Bionano Genomics' stronger consensus rating and higher possible upside, analysts clearly believe Bionano Genomics is more favorable than Precipio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precipio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Precipio has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market. Comparatively, Bionano Genomics has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market.

Precipio has a net margin of -3.57% compared to Bionano Genomics' net margin of -109.94%. Precipio's return on equity of -6.73% beat Bionano Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precipio	-3.57%	-6.73%	-4.49%
Bionano Genomics	-109.94%	-71.38%	-43.07%

In the previous week, Precipio and Precipio both had 5 articles in the media. Precipio's average media sentiment score of 0.52 beat Bionano Genomics' score of 0.46 indicating that Precipio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precipio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bionano Genomics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Precipio has higher earnings, but lower revenue than Bionano Genomics. Precipio is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precipio	$24.05M	1.64	-$360K	-$0.47	N/A
Bionano Genomics	$28.51M	0.47	-$26.40M	-$4.37	N/A

10.5% of Precipio shares are owned by institutional investors. Comparatively, 11.4% of Bionano Genomics shares are owned by institutional investors. 16.6% of Precipio shares are owned by insiders. Comparatively, 0.7% of Bionano Genomics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Precipio beats Bionano Genomics on 8 of the 15 factors compared between the two stocks.

How does Bionano Genomics compare to Data I/O?

Bionano Genomics (NASDAQ:BNGO) and Data I/O (NASDAQ:DAIO) are both small-cap measuring and control equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

11.4% of Bionano Genomics shares are owned by institutional investors. Comparatively, 37.0% of Data I/O shares are owned by institutional investors. 0.7% of Bionano Genomics shares are owned by company insiders. Comparatively, 4.1% of Data I/O shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Data I/O has lower revenue, but higher earnings than Bionano Genomics. Data I/O is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionano Genomics	$28.51M	0.47	-$26.40M	-$4.37	N/A
Data I/O	$18.57M	2.06	-$5.24M	-$0.84	N/A

Bionano Genomics presently has a consensus target price of $6.00, suggesting a potential upside of 415.02%. Data I/O has a consensus target price of $5.11, suggesting a potential upside of 25.74%. Given Bionano Genomics' higher possible upside, equities analysts plainly believe Bionano Genomics is more favorable than Data I/O.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Data I/O	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.80

Bionano Genomics has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market. Comparatively, Data I/O has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

In the previous week, Bionano Genomics had 4 more articles in the media than Data I/O. MarketBeat recorded 5 mentions for Bionano Genomics and 1 mentions for Data I/O. Data I/O's average media sentiment score of 1.89 beat Bionano Genomics' score of 0.46 indicating that Data I/O is being referred to more favorably in the news media.

Company	Overall Sentiment
Bionano Genomics	Neutral
Data I/O	Very Positive

Data I/O has a net margin of -41.85% compared to Bionano Genomics' net margin of -109.94%. Data I/O's return on equity of -54.33% beat Bionano Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bionano Genomics	-109.94%	-71.38%	-43.07%
Data I/O	-41.85%	-54.33%	-36.75%

Summary

Data I/O beats Bionano Genomics on 11 of the 16 factors compared between the two stocks.

How does Bionano Genomics compare to Autoscope Technologies?

Bionano Genomics (NASDAQ:BNGO) and Autoscope Technologies (NASDAQ:AATC) are both small-cap measuring and control equipment companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

Bionano Genomics currently has a consensus price target of $6.00, indicating a potential upside of 415.02%. Given Bionano Genomics' stronger consensus rating and higher probable upside, research analysts clearly believe Bionano Genomics is more favorable than Autoscope Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Autoscope Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Bionano Genomics had 4 more articles in the media than Autoscope Technologies. MarketBeat recorded 5 mentions for Bionano Genomics and 1 mentions for Autoscope Technologies. Bionano Genomics' average media sentiment score of 0.46 beat Autoscope Technologies' score of 0.00 indicating that Bionano Genomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bionano Genomics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Autoscope Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Autoscope Technologies has lower revenue, but higher earnings than Bionano Genomics. Bionano Genomics is trading at a lower price-to-earnings ratio than Autoscope Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionano Genomics	$28.51M	0.47	-$26.40M	-$4.37	N/A
Autoscope Technologies	$12.89M	2.26	$6.62M	$0.25	21.20

Autoscope Technologies has a net margin of 37.59% compared to Bionano Genomics' net margin of -109.94%. Autoscope Technologies' return on equity of 27.06% beat Bionano Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bionano Genomics	-109.94%	-71.38%	-43.07%
Autoscope Technologies	37.59%	27.06%	23.97%

11.4% of Bionano Genomics shares are owned by institutional investors. 0.7% of Bionano Genomics shares are owned by company insiders. Comparatively, 21.6% of Autoscope Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Bionano Genomics has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market. Comparatively, Autoscope Technologies has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

Summary

Bionano Genomics and Autoscope Technologies tied by winning 8 of the 16 factors compared between the two stocks.

How does Bionano Genomics compare to ClearSign Technologies?

Bionano Genomics (NASDAQ:BNGO) and ClearSign Technologies (NASDAQ:CLIR) are both small-cap measuring and control equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

ClearSign Technologies has lower revenue, but higher earnings than Bionano Genomics. ClearSign Technologies is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionano Genomics	$28.51M	0.47	-$26.40M	-$4.37	N/A
ClearSign Technologies	$5.23M	4.29	-$5.50M	-$0.99	N/A

Bionano Genomics currently has a consensus price target of $6.00, indicating a potential upside of 415.02%. ClearSign Technologies has a consensus price target of $20.00, indicating a potential upside of 382.51%. Given Bionano Genomics' higher probable upside, analysts plainly believe Bionano Genomics is more favorable than ClearSign Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ClearSign Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Bionano Genomics had 3 more articles in the media than ClearSign Technologies. MarketBeat recorded 5 mentions for Bionano Genomics and 2 mentions for ClearSign Technologies. ClearSign Technologies' average media sentiment score of 0.93 beat Bionano Genomics' score of 0.46 indicating that ClearSign Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bionano Genomics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ClearSign Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bionano Genomics has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market. Comparatively, ClearSign Technologies has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market.

11.4% of Bionano Genomics shares are held by institutional investors. Comparatively, 24.0% of ClearSign Technologies shares are held by institutional investors. 0.7% of Bionano Genomics shares are held by insiders. Comparatively, 5.2% of ClearSign Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Bionano Genomics has a net margin of -109.94% compared to ClearSign Technologies' net margin of -111.66%. ClearSign Technologies' return on equity of -61.24% beat Bionano Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bionano Genomics	-109.94%	-71.38%	-43.07%
ClearSign Technologies	-111.66%	-61.24%	-45.80%

Summary

Bionano Genomics and ClearSign Technologies tied by winning 7 of the 14 factors compared between the two stocks.

How does Bionano Genomics compare to MultiSensor AI?

Bionano Genomics (NASDAQ:BNGO) and MultiSensor AI (NASDAQ:MSAI) are both small-cap measuring and control equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

Bionano Genomics currently has a consensus price target of $6.00, suggesting a potential upside of 415.02%. MultiSensor AI has a consensus price target of $120.00, suggesting a potential upside of 1,976.48%. Given MultiSensor AI's stronger consensus rating and higher possible upside, analysts clearly believe MultiSensor AI is more favorable than Bionano Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MultiSensor AI	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Bionano Genomics has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market. Comparatively, MultiSensor AI has a beta of -0.26, indicating that its share price is 126% less volatile than the broader market.

In the previous week, Bionano Genomics had 4 more articles in the media than MultiSensor AI. MarketBeat recorded 5 mentions for Bionano Genomics and 1 mentions for MultiSensor AI. MultiSensor AI's average media sentiment score of 1.87 beat Bionano Genomics' score of 0.46 indicating that MultiSensor AI is being referred to more favorably in the news media.

Company	Overall Sentiment
Bionano Genomics	Neutral
MultiSensor AI	Very Positive

11.4% of Bionano Genomics shares are owned by institutional investors. Comparatively, 82.3% of MultiSensor AI shares are owned by institutional investors. 0.7% of Bionano Genomics shares are owned by insiders. Comparatively, 50.8% of MultiSensor AI shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Bionano Genomics has a net margin of -109.94% compared to MultiSensor AI's net margin of -162.60%. MultiSensor AI's return on equity of -48.87% beat Bionano Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bionano Genomics	-109.94%	-71.38%	-43.07%
MultiSensor AI	-162.60%	-48.87%	-41.13%

MultiSensor AI has lower revenue, but higher earnings than Bionano Genomics. MultiSensor AI is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionano Genomics	$28.51M	0.47	-$26.40M	-$4.37	N/A
MultiSensor AI	$5.55M	2.10	-$11.71M	-$8.43	N/A

Summary

MultiSensor AI beats Bionano Genomics on 10 of the 17 factors compared between the two stocks.

Get Bionano Genomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNGO vs. The Competition

Export

Metric	Bionano Genomics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.37M	$3.40B	$6.50B	$12.36B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	-0.27	20.08	23.99	24.69
Price / Sales	0.47	322.83	538.03	166.93
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	0.27	8.06	10.47	6.82
Net Income	-$26.40M	$23.89M	$3.56B	$337.45M
7 Day Performance	-0.43%	2.75%	1.21%	2.49%
1 Month Performance	1.30%	0.70%	2.14%	4.37%
1 Year Performance	-68.08%	45.69%	26.24%	32.80%

Bionano Genomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNGO Bionano Genomics	2.6671 of 5 stars	$1.17 +0.4%	$6.00 +415.0%	-68.2%	$13.37M	$28.51M	N/A	300	Analyst Upgrade
PRPO Precipio	1.198 of 5 stars	$23.00 -2.1%	N/A	+103.7%	$41.99M	$24.05M	N/A	60
DAIO Data I/O	3.2819 of 5 stars	$3.60 flat	$5.11 +41.9%	+43.9%	$33.82M	$21.50M	N/A	100
AATC Autoscope Technologies	N/A	$5.37 -2.4%	N/A	-29.2%	$29.59M	$12.89M	6.10	40
CLIR ClearSign Technologies	3.4041 of 5 stars	$4.15 +5.3%	$20.00 +381.9%	-32.0%	$21.33M	$5.23M	N/A	10	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNGO) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bionano Genomics (BNGO) Competitors

BNGO vs. PRPO, DAIO, AATC, CLIR, and MSAI

How does Bionano Genomics compare to Precipio?

Summary

How does Bionano Genomics compare to Data I/O?

Summary

How does Bionano Genomics compare to Autoscope Technologies?

Summary

How does Bionano Genomics compare to ClearSign Technologies?

Summary

How does Bionano Genomics compare to MultiSensor AI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNGO vs. The Competition

Bionano Genomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bionano Genomics (BNGO) Competitors

BNGO vs. PRPO, DAIO, AATC, CLIR, and MSAI

How does Bionano Genomics compare to Precipio?

Do analysts recommend PRPO or BNGO?

Which has more volatility & risk, PRPO or BNGO?

Is PRPO or BNGO more profitable?

Does the media favor PRPO or BNGO?

Which has preferable earnings and valuation, PRPO or BNGO?

Do insiders & institutionals believe in PRPO or BNGO?

Summary

How does Bionano Genomics compare to Data I/O?

Do institutionals & insiders hold more shares of BNGO or DAIO?

Which has better valuation and earnings, BNGO or DAIO?

Do analysts recommend BNGO or DAIO?

Which has more volatility & risk, BNGO or DAIO?

Does the media prefer BNGO or DAIO?

Is BNGO or DAIO more profitable?

Summary

How does Bionano Genomics compare to Autoscope Technologies?

Do analysts rate BNGO or AATC?

Does the media refer more to BNGO or AATC?

Which has better valuation and earnings, BNGO or AATC?

Is BNGO or AATC more profitable?

Do institutionals and insiders have more ownership in BNGO or AATC?

Which has more risk & volatility, BNGO or AATC?

Summary

How does Bionano Genomics compare to ClearSign Technologies?

Which has preferable earnings and valuation, BNGO or CLIR?

Do analysts recommend BNGO or CLIR?

Does the media favor BNGO or CLIR?

Which has more risk & volatility, BNGO or CLIR?

Do insiders and institutionals have more ownership in BNGO or CLIR?

Is BNGO or CLIR more profitable?

Summary

How does Bionano Genomics compare to MultiSensor AI?

Do analysts rate BNGO or MSAI?

Which has more volatility and risk, BNGO or MSAI?

Does the media favor BNGO or MSAI?

Do institutionals & insiders hold more shares of BNGO or MSAI?

Is BNGO or MSAI more profitable?

Which has higher valuation & earnings, BNGO or MSAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNGO vs. The Competition

Bionano Genomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools